KPIs & Operating Metrics(New)
Growth Metrics

Bristol Myers Squibb (BMY) Cash from Operations (2016 - 2026)

Bristol Myers Squibb has reported Cash from Operations over the past 18 years, most recently at 1104000000.0 for Q1 2026.

  • Quarterly Cash from Operations fell 43.5% to 1104000000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 13306000000.0 through Mar 2026, down 7.02% year-over-year, with the annual reading at 14156000000.0 for FY2025, 6.81% down from the prior year.
  • Cash from Operations was 1104000000.0 for Q1 2026 at Bristol Myers Squibb, down from 1974000000.0 in the prior quarter.
  • Over five years, Cash from Operations peaked at 6311000000.0 in Q3 2025 and troughed at 1104000000.0 in Q1 2026.
  • The 5-year median for Cash from Operations is 3306000000.0 (2022), against an average of 3375058823.53.
  • The largest YoY upside for Cash from Operations was 68.4% in 2025 against a maximum downside of 55.53% in 2025.
  • A 5-year view of Cash from Operations shows it stood at 3306000000.0 in 2022, then rose by 28.61% to 4252000000.0 in 2023, then grew by 4.4% to 4439000000.0 in 2024, then crashed by 55.53% to 1974000000.0 in 2025, then tumbled by 44.07% to 1104000000.0 in 2026.
  • Per Business Quant, the three most recent readings for BMY's Cash from Operations are 1104000000.0 (Q1 2026), 1974000000.0 (Q4 2025), and 6311000000.0 (Q3 2025).